Danske Bank’s Adverum Biotechnologies ADVM Stock Holding History

Danske Bank’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2	Closed	-$14	–	1412
2024 Q3	$14	Buy	+2	New	+$15	﹤0.01%	1514

Other funds holding ADVM

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWA

Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Danske Bank's ADVM Position: Q4 2024 in Review

Danske Bank sold out of Adverum Biotechnologies (ADVM) in Q4 2024, closing a stake of 2 shares — an estimated $14 sold.

Danske Bank first reported a position in ADVM in Q3 2024 and held it in 1 quarter. The position peaked at $14 in Q3 2024. 69 funds tracked by Wall St. Rank hold ADVM as of Q4 2024.

Danske Bank reported no remaining Adverum Biotechnologies position as of Q4 2024 after selling out during the quarter.
Danske Bank sold 2 Adverum Biotechnologies shares in Q4 2024, an estimated $14.
Danske Bank first reported a position in Adverum Biotechnologies in Q3 2024 and held it in 1 quarter.
Danske Bank's Adverum Biotechnologies position peaked at $14 in Q3 2024.
69 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2024.

Based on Danske Bank's 13F filing for Q4 2024, filed 18 Mar 2026.